Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,1,1-trifluoro-3-((N-acetyl)-L-leucylamido)-4-phenyl-butan-2-one(N-acetyl-L-leucyl-L-phenylalanyl trifluoromethyl ketone)
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
1,1,1-Trifluoro-3-(N-acetyl-L-leucylamido)-4-phenyl-butan-2-one(N-acetyl-L-leucyl-L‑phenylalanyl trifluoromethyl ketone) is a synthetic small molecule peptidomimetic compound. It contains a peptide backbone with an N-terminal acetyleucine and phenylanine moiety linked to a trifluoromethyl ketone group. The compound is primarily used as an experimental tool in biochemical research and has not been approved for clinical use. Its mechanism of action is presumed to involve inhibition of serine proteases or related enzymes due to the presence of the trifluoromethyl ketone warhead—a known electrophilic group that can form covalent adducts with active site serines in proteases. There are no known approved indications or marketed products containing this molecule[1][2][5].
- Other names
- N-acetyl-leucyl-phenylalanyl trifluoromethyl ketone(2S)-2-acetamido-4-methyl-N-[(2S)-4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl]pentanamide
02
Targets
PRSS1 (Trypsin family)
Beyond the preview
Go deeper on 1,1,1-trifluoro-3-((N-acetyl)-L-leucylamido)-4-phenyl-butan-2-one(N-acetyl-L-leucyl-L-phenylalanyl trifluoromethyl ketone).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1,1,1-trifluoro-3-((N-acetyl)-L-leucylamido)-4-phenyl-butan-2-one(N-acetyl-L-leucyl-L-phenylalanyl trifluoromethyl ketone).